Inhibition of Pig Phosphoenolpyruvate Carboxykinase Isoenzymes by 3-Mercaptopicolinic Acid and Novel Inhibitors

Jorge Hidalgo; Pedro Latorre; José Alberto Carrodeguas; Adrián Velázquez-Campoy; Javier Sancho; Pascual López-Buesa

doi:10.1371/journal.pone.0159002

Abstract

There exist two isoforms of cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C) in pig populations that differ in a single amino acid (Met139Leu). The isoenzymes have different kinetic properties, affecting more strongly the K_m and V_max of nucleotides. They are associated to different phenotypes modifying traits of considerable economic interest. In this work we use inhibitors of phosphoenolpyruvate carboxykinase activity to search for further differences between these isoenzymes. On the one hand we have used the well-known inhibitor 3-mercaptopicolinic acid. Its inhibition patterns were the same for both isoenzymes: a three-fold decrease of the K_i values for GTP in 139Met and 139Leu (273 and 873 μM, respectively). On the other hand, through screening of a chemical library we have found two novel compounds with inhibitory effects of a similar magnitude to that of 3-mercaptopicolinic acid but with less solubility and specificity. One of these novel compounds, (N'1-({5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl}methylidene)-2,4-dichlorobenzene-1-carbohydrazide), exhibited significantly different inhibitory effects on either isoenzyme: it enhanced threefold the apparent K_m value for GTP in 139Met, whereas in 139Leu, it reduced it from 99 to 69 μM. The finding of those significant differences in the binding of GTP reinforces the hypothesis that the Met139Leu substitution affects strongly the nucleotide binding site of PEPCK-C.

Citation: Hidalgo J, Latorre P, Carrodeguas JA, Velázquez-Campoy A, Sancho J, López-Buesa P (2016) Inhibition of Pig Phosphoenolpyruvate Carboxykinase Isoenzymes by 3-Mercaptopicolinic Acid and Novel Inhibitors. PLoS ONE 11(7): e0159002. https://doi.org/10.1371/journal.pone.0159002

Editor: Israel Silman, Weizmann Institute of Science, ISRAEL

Received: February 2, 2016; Accepted: June 25, 2016; Published: July 8, 2016

Copyright: © 2016 Hidalgo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting Information files.

Funding: This study was supported by research grants AGL2008-01487ALI (www.mineco.gob.es), DGA-IAF FITE2012/2013 (www.aragob.es), and UZ2014-CIE-03 (www.unizar.es) to P.L.B., AGL2015-66177 to P.L.B. and J.A.C., and grants BFU2013-47064-P (www.micinn.es), BIO2014-57314-REDT (www.mineco.gob.es) and PI078/08 to J.S. P.L. was supported by a predoctoral fellowship of Fundación La Caixa. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Mammalian cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C, EC 4.1.1.32) catalyzes the GTP-dependent phosphorylation of OAA to yield PEP, GDP and CO₂. The reverse reaction is possible, however it is unlikely to occur in vivo because the K_m for PEP is higher than its physiological concentrations [1–2]. PEPCK-C is situated in a crossroad of metabolic pathways; it is the main regulatory enzyme of gluconeogenesis and, in some tissues, of glyceroneogenesis. It also serves as regulator of the tricarboxylic acid cycle and is involved in serine biosynthesis [3]. Due to its gluconeogenic function, PEPCK-C activity favors pathological processes such as diabetes and cancer [4–7]. The involvement of PEPCK-C in glyceroneogenesis is convincingly illustrated by the supermouse generated by Hakimi et al. [8] in which a 100-fold overexpression of PEPCK-C in striated muscular tissue resulted in a 4-fold enhancement of intramuscular triglyceride content and a concomitant reduction of both visceral and abdominal fat.

We have recently found in pigs two isoforms of PEPCK-C differing in a single amino acid residue far away from the active center (Met139Leu) and exhibiting reduced and enhanced k_cat values in the gluconeogenic/glyceroneogenic reaction (OAA → PEP) and the reverse one (PEP → OAA), respectively [9]. Accordingly to the enzyme role in glyceroneogenesis, pigs carrying the 139Leu PEPCK-C (the one with lower k_cat values in the glyceroneogenic direction) had lower intramuscular fat content. Other negative phenotypic effects associated to the Met139Leu substitution in pigs were an increase in backfat thickness and lower meat quality due to enhanced postmortem exudation. The high frequency of 139Leu PEPCK-C alleles in modern pig breeds together with the set of negative effects associated to it makes the study of the pig isoenzymes of considerable economic relevance.

The main regulatory mechanism of PEPCK-C is transcriptional [10–11], although reversible acetylation of lysine residues has been shown to regulate also PEPCK-C stability in vivo [12]. In spite of its metabolic relevance, no known allosteric effector of PEPCK-C has been found to be physiologically relevant in vivo. Clearly, finding allosteric effectors of PEPCK-C could be interesting to modulate its activity in humans. In this respect, PEPCK-C inhibitors could be alternatives to ameliorate diabetes or to reduce high glucose levels needed by cancer cells [13].

The search for new ligands can focus on structural similarity of ligands with substrates or can be based on the known 3D structure of the enzyme, especially on its active site [14]. However, these strategies usually allow the finding of only inhibitors. Several such PEPCK-C inhibitors have been already described, most of which are structural analogues of substrates acting as competitive inhibitors that bind to the active site and few of them are non-competitive [15–17]. PEPCK-C inhibitors may help to investigate biochemical or functional differences between PEPCK-C isoenzymes. Alternatively, enzyme effectors can be identified by screening chemical libraries, a strategy that is being increasingly used to find molecules with a variety of biological effects [18–19].

In this work we pursue a double objective: to study more thoroughly the biochemical properties of pig PEPCK-C isoenzymes using a well-known inhibitor (3-mercaptopicolinic acid, 3-MP) and to identify new PEPCK-C effectors by screening a chemical library against the mentioned pig PEPCK-C isoenzymes.

Materials and Methods

2.1. Enzymes and chemicals

Oxaloacetic acid (OAA), GTP, GDP, dithiothreitol (DTT), NADH, HEPES, 8-anilino-1-naphthalenesulfonic acid (ANS), dimethyl sulfoxide (DMSO), tris-(2-carboxyethyl) phosphine (TCEP), mineral oil and enzymes malate dehydrogenase (600–1000 units/mg), pyruvate kinase (600–1000 units/mL) and lactate dehydrogenase (900–1400 units/mL) were purchased from Sigma-Aldrich (USA). Phosphoenolpyruvate was obtained from Bachem (Switzerland). MnCl₂, MgCl₂ and KHCO₃ were acquired from Panreac (Spain). 3-mercaptopicolinic acid (3-MP) was obtained from Sta. Cruz Biotechnology (USA). A chemical library of 10,000 compounds (HitFinder) and the subsequent positive compounds (N1-cyclohexyl-2-{1-[4-methyl-2-(2-thienyl)-1,3-thiazol-5-yl]ethylidene}hydrazine-1-carbothiamide, or compound 1, and N'1-({5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl}methylidene)-2,4-dichlorobenzene-1-carbohydrazide, or compound 2, were purchased from Maybridge (UK).

2.2. PEPCK-C purification

PEPCK-C 139Met and 139Leu were purified as described in Latorre et al. [9]. In brief, Escherichia coli BL21 (DE3) with the appropriate constructs were grown in LB + ampicillin medium and then protein expression was induced with IPTG. Clarified bacteria lysates were purified by affinity chromatography on cobalt column (GE Healthcare). Kinetic assays were performed with His-tagged PEPCK-C, which behaved almost identically to the non His-tagged enzyme [2]. For screening, CD spectroscopy and ITC measurements, the His-tag was removed by PreScission Protease (GE Healthcare) at 4°C overnight.

2.3. Screening of chemical library

PEPCK-C effectors were identified from a chemical library using a screening procedure based on a thermal-shift assay [20–21]. Potential protein effector compounds were dispensed into 96-well microplates. Each well contained 4 μM PEPCK-C in a 20 mM HEPES buffer pH 7.4, plus 1 mM TCEP, 100 μM ANS, 10% DMSO and either 1 or 5 chemical library compounds, each at a 25 μM concentration. Previous experiments showed that PEPCK-C tolerates up to 12% DMSO (data not shown). 50 μL of mineral oil were added to each well to prevent evaporation. In a first screening round, 5 different compounds were present in each well. The binding of effectors to PEPCK-C was assessed by monitoring the thermal denaturation of the enzyme and identifying compounds inducing a stabilizing effect (increase in the unfolding temperature, T_m, compared to the free enzyme) in a FluoDia T70 High Temperature Fluorescence Microplate Reader (Photon Technology International, UK). To obtain T_m values, unfolding curves were fitted to Boltzmann function (Eq 1) using OriginPro 9.1 software. (1) where A₁ and A₂ are the asymptotic values of the signal in the pre- and post-transition region of the unfolding curve, respectively, and S is a parameter associated with the slope of the unfolding curve at the T_m and related to the unfolding enthalpy of the enzyme. A given well was considered as a positive hit if its associated T_m value was 8°C higher than the T_m found in control wells lacking added library compounds. In a second round, the compounds present in the positive wells were individually analyzed to identify the binders.

2.4. Enzymatic assays

PEPCK-C activity was measured in an UNICAM 500 spectrometer (UNICAM Analytical Systems, UK) with coupled spectrophotometric assays using pyruvate kinase and lactate dehydrogenase as auxiliary enzymes in PEP synthesis reaction and malate dehydrogenase in the reverse reaction.

Assays to calculate IC₅₀ values were performed in the direction of OAA synthesis in 1 mL of a 100 mM HEPES buffer pH 7.4, containing 10 mM DTT, 0.2 mM MnCl₂, 2 mM MgCl₂, 2 mM GDP, 0.2 mM NADH, 2 mM PEP, 100 mM KHCO₃ and 4 units of malate dehydrogenase. Variable inhibitor concentrations of 0–200 μM were also used. Assays were initiated by PEPCK-C addition. Rates were calculated by measuring the decreasing slope of absorbance at 340 nm after subtracting the rate of spontaneous NADH oxidation.

3-MP inhibitions assays in OAA synthesis direction were carried out as described before with the exception of the variable substrate (50–600 μM for PEP and 10–100 μM for GDP) and 3-MP concentration (10–100 μM). Assays in the direction of PEP synthesis were performed in 1 mL of a 100 mM HEPES buffer pH 7.4, containing 10 mM DTT, 0.2 mM MnCl₂, 2 mM MgCl₂, 1 mM GTP or 400 μM OAA, 1 mM ADP, 0.2 mM NADH, PEPCK-C and 5 units of each pyruvate kinase and lactate dehydrogenase. Reactions were initiated by addition of OAA. Variable substrates were 5–50 μM OAA or 25–500 μM GTP and 3-MP concentrations were between 10–400 μM. Rates were calculated by measuring the decreasing slope at 340 nm of absorbance after subtracting the rate of spontaneous NADH oxidation in the case of OAA synthesis or the rate of the blank which contained all the components of the mix but PEPCK-C in the case of PEP synthesis.

To investigate the possible inhibition of auxiliary enzymes by compound 1 and 2 the following assay was performed in 1 mL of a 100 mM HEPES buffer pH 7.4, containing 10 mM DTT, 0.2 mM MnCl₂, 2 mM MgCl₂, 2 mM GDP, 0.2 mM NADH, 2 mM PEP, 1 mM ADP, 100 mM KHCO₃ and 25–200 μM compound 1 or 2. Reactions were initiated by addition of 0.5 units of each pyruvate kinase and lactate dehydrogenase.

Compound 1 and 2 inhibitions assays were performed in PEP synthesis direction as described in 3-MP inhibition assays. Variable substrates were 10–100 μM OAA or 25–500 μM GTP, inhibitors concentrations were around IC₅₀ value (100 μM compound 1 or 50 μM compound 2) and 20 units of each pyruvate kinase and lactate dehydrogenase were also added. The units of pyruvate kinase and lactate dehydrogenase were increased four times in these assays due to slight interaction of compounds 1 and 2 with these enzymes.

2.5. Determination of kinetic parameters

IC₅₀ value represents the inhibitor concentration required to reduce activity by 50%. Concentration-dependent inhibition data were fitted to a linear or a quadratic function using GraphPad Prism 3.03 software. 3-MP inhibition assays were fitted in double reciprocal plots. To describe the mixed non-competitive inhibition, the double reciprocal equation can be written as: (2)

Secondary plots to calculate K_i and αK_i values can be constructed from: (3) (4)

K_i and αK_i are the dissociation constants of the enzyme-inhibitor complex and the enzyme-inhibitor-substrate complex, respectively.

K_i values with respect to GTP and GDP were calculated by Dixon plots with all substrates at saturating concentration because 3-MP produced an uncompetitive inhibition. The equation for the Dixon plot is: (5)

Data from compound 1 and 2 inhibition assays were represented in double reciprocal plots to calculate V_max and K_m values using GraphPad Prism 3.03 software.

2.6. Circular dichroism (CD)

PEPCK-C was diluted to 20 μM in a 20 mM HEPES pH 7.4 buffer, containing 1 mM TCEP. 50 μM 3-MP, compound 1 or compound 2 were added to the PEPCK-C solution. Readings were performed at 25°C in a 0.1 cm cuvette from 320 to 250 nm in a Chirascan CD-spectrophotometer (Applied Photophysics, UK). CD spectra were calculated after subtracting the blank which contained all the components except PEPCK-C.

2.7. Isothermal titration calorimetry (ITC)

Isothermal titration calorimetry (ITC) experiments were performed using an Auto-iTC200 microcalorimeter (MicroCal, Malvern, UK) at 25°C. The reference cell was filled with distilled water. The sample cell was loaded with 10 μM PEPCK-C 139M or 139L in a 20 mM HEPES pH 7.4 buffer, containing 150 mM NaCl, 1 mM TCEP and 6.7% DMSO. 2 mM GTP was also added to the enzyme solution in the corresponding experiments. The syringe was loaded with 400 μM 3-MP or 100 μM compound 2 in a 20 mM HEPES pH 7.4 buffer, containing 150 mM NaCl, 1 mM TCEP and 6.7% DMSO. In all the assays, a total of 19 injections of 2 μL were added sequentially to the sample cell with a 150 s spacing to ensure that the thermal power signal returned to the baseline prior to the next injection. The binding isotherms (normalized heat effect as a function of the molar ratio) were analyzed with Origin 7 (OriginLab) using a single class of binding sites model. Calorimetric assays were perform in duplicates at least.

2.8. Statistical analysis

Comparisons between 139Met and 139Leu K_i and between 139Met and 139Leu αK_i in 3-MP kinetics were performed using two-sample t-tests. p<0.05 was considered statistically significant. Compound 1 and 2 kinetic experiments were also analyzed using two-sample t-tests comparing 139Met and 139Leu K_m at the same inhibition range (0 or 50 μM) and 139Met and 139Leu V_max at the same inhibition range (0 or 50 μM). p<0.05 was considered statistically significant.

Results

3.1. Inhibition with 3-MP

To investigate the biochemical properties of porcine PEPCK-C isoenzymes we used a well-known PEPCK-C inhibitor, 3-MP. We first determined IC₅₀ values of wild type PEPCK-C at saturating substrate concentration in the direction of OAA synthesis. An IC₅₀ value of 65 ± 6 μM was found (S1 Fig). This value is useful to select the inhibitor concentration range in further kinetic experiments.

We then studied the inhibition patterns by 3-MP of the two PEPCK-C isoenzymes.

The patterns were different for the two substrates of the reverse reaction (OAA synthesis); whereas 3-MP behaved as a mixed non-competitive inhibitor when PEP was used as variable substrate, it behaved as an uncompetitive inhibitor when GDP was used as a variable substrate (Fig 1 and S2 Fig).

Download:

Fig 1. Double reciprocals and secondary plots of 3-MP adding PEP and GDP as variable substrates.

(A-C) Double reciprocal, slopes and intercepts of 139Met varying PEP. (D-F) Double reciprocal, slopes and intercepts of 139Leu varying PEP. (G) Double reciprocal of 139Met varying GDP. (H) Double reciprocal of 139Leu varying GDP. 139Met and 139Leu were assayed as described in Materials and Methods with increasing concentration of substrates (50–600 μM for PEP, 10–100 μM for GDP) and 3-MP concentration between 10–100 μM.

https://doi.org/10.1371/journal.pone.0159002.g001

When the effect of 3-MP was studied on the glyceroneogenic reaction, the inhibition patterns were exactly the same as the observed in the reverse reaction; 3-MP behaved as an uncompetitive inhibitor when using a nucleotide (GTP in this case) as a variable substrate and as a mixed non-competitive inhibitor when using OAA as a variable substrate (Fig 2 and S3 Fig).

Download:

Fig 2. Double reciprocals and secondary plots of 3-MP adding OAA and GTP as variable substrates.

(A-C) Double reciprocal, slopes and intercepts of 139Met varying OAA. (D-F) Double reciprocal, slopes and intercepts of 139Leu varying OAA. (G) Double reciprocal of 139Met varying GTP. (H) Double reciprocal of 139Leu varying GTP.139Met and 139Leu were assayed as described in Materials and Methods with increasing concentration of substrates (5–50 μM for OAA, 25–500 μM for GTP) and 3-MP concentration between 10–100 μM for OAA and between 50–400 μM for GTP.

https://doi.org/10.1371/journal.pone.0159002.g002

We found no significant differences between 139Met and 139Leu in the reverse reaction. PEP K_i values were 16 ± 2 μM and 19 ± 4 μM and αK_i values were 20 ± 4 μM and 31 ± 5 μM for 139Met and 139Leu, respectively. K_i values with respect to GDP were 45 μM for both isoenzymes.

K_i values for glyceroneogenic substrates showed significant differences: they were 3 and 1.6 fold lower for 139Met when using GTP and OAA as variable substrates, respectively. However, αK_i value with respect to OAA showed no significant differences. All the K_i and αK_i values are presented in Table 1.

Download:

Table 1. K_i and αK_i values and inhibition patterns of PEPCK-C isoenzymes in presence of 3-MP.

https://doi.org/10.1371/journal.pone.0159002.t001

3.2. Screening of chemical library

To search for new PEPCK-C effectors we used a 10,000-compound chemical library from Maybridge and the 139Met enzyme. Initial screening was performed using 5 compounds per well. Afterwards, compounds in positive wells were analyzed individually. A change in unfolding temperature, measured by fluorescence, was used as indicator for a positive hit (see Fig 3). In the first round 7 hits were identified with T_m values of 55.5 ± 0.1, 56.4 ± 0.3, 48.1 ± 0.1, 53.9 ± 0.2, 56.9 ± 0.2, 53.0 ± 0.3 and 52.6 ± 0.1°C, well above the unfolding temperature determined in control wells (41.8 ± 0.1°C).

Download:

Fig 3. Thermal unfolding of PEPCK-C in presence and absence of compound 1 or 2.

https://doi.org/10.1371/journal.pone.0159002.g003

The 35 compounds contained in the 7 positive wells of the first screening were then analyzed individually. In this screening we found only two hits with T_m values of 50.9 ± 0.1 and 50.0 ± 0.1, which is about 8°C higher than controls. The absence of positive hits in the remainder wells can be attributed to a previous accumulative stabilizing effect of the compounds in the initial positive wells or just be false positives.

The identified compounds were N1-cyclohexyl-2-{1-[4-methyl-2-(2-thienyl)-1,3-thiazol-5-yl]ethylidene}hydrazine-1-carbothiamide, or compound 1, and N'1-({5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl}methylidene)-2,4-dichlorobenzene-1-carbohydrazide, or compound 2 (Fig 4). Compounds 1 and 2 were selected for subsequent kinetic analysis.

Download:

Fig 4. Structural formula of compounds 1 and 2.

https://doi.org/10.1371/journal.pone.0159002.g004

3.3. Inhibition with compound 1

We first calculated IC₅₀ values at saturating substrate concentrations assaying the activity in the direction of OAA synthesis. Compound 1 showed an IC₅₀ value of 134 ± 4 μM (S4 Fig). This value was higher than that obtained for 3-MP (65 ± 6 μM. Concentrations above 250 μM resulted in precipitation of compound 1 due to its poor solubility. Compound 1 additionally showed a slight inhibition of the auxiliary enzymes pyruvate kinase and lactate dehydrogenase (data not shown), which was solved by increasing four times the concentration of the auxiliary enzymes. Due to the mentioned low solubility problems we decided to perform for compound 1 a more simple analysis of inhibition than the one performed with 3-MP. We calculated only the change in V_max and K_m values, instead of K_i values, using an inhibitor concentration around its IC₅₀.

When using OAA as variable substrate we found a drop in V_max value (from 21.3 to 6.7 μmol min^-1 mg^-1 in 139Met and from 21.8 to 9.4 μmol min^-1 mg^-1 in 139Leu) and no change in K_m (Fig 5). There were no significant differences in V_max or K_m between 139Met and 139Leu (Table 2).

Download:

Fig 5. Double reciprocal plots of compound 1 inhibition varying glyceroneogenic substrates.

https://doi.org/10.1371/journal.pone.0159002.g005

Download:

Table 2. V_max and K_m values and inhibition patterns of PEPCK-C isoenzymes in the presence of glyceroneogenic substrates and compound 1.

https://doi.org/10.1371/journal.pone.0159002.t002

Nevertheless, when GTP was used as variable substrate V_max values were reduced from 20.0 to 7.8 μmol min^-1 mg^-1 and from 22.5 to 7.2 μmol min^-1 mg^-1 for 139Met and 139Leu, respectively. K_m values raised from 96 and 99 to 118 and 155 μM in 139Met and 139Leu, respectively. There were also no significant differences between PEPCK-C isoenzymes (Table 2).

3.4. Inhibition with compound 2

IC₅₀ value for compound 2 was 30 ± 2 μM (S4 Fig). This value was lower than those of 3-MP (65 ± 6 μM) or compound 1 (134 ± 4 μM). Compound 2 also presented poor solubility and a slight interaction with auxiliary enzymes, what made necessary a four-fold increase in the amount of auxiliary enzymes added to the assays.

V_max values for OAA in the presence of the inhibitor were reduced from 21.3 to 4.6 μmol min^-1 mg^-1 in the case of 139Met and from 21.8 to 12.7 μmol min^-1 mg^-1 in the case of 139Leu. This change was significantly different between 139Met and 139Leu, the former isoform being more sensitive to inhibition by compound 2. K_m values remained constant (Fig 6).

Download:

Fig 6. Double reciprocal plots of compound 2 inhibition varying glyceroneogenic substrates.

https://doi.org/10.1371/journal.pone.0159002.g006

When using GTP as a variable substrate, we found significant differences between isoenzymes: whereas 139Met K_m value was raised in the presence of the inhibitor over 2.5 fold, 139Leu K_m value was reduced by about 30% (see Table 3). No significant change was observed in the effect of compound 2 on V_max values of 139Met and 139Leu.

Download:

Table 3. V_max and K_m values and inhibition patterns of PEPCK-C isoenzymes in the presence of glyceroneogenic substrates and compound 2.

https://doi.org/10.1371/journal.pone.0159002.t003

3.5. CD spectra

The near UV-CD spectra of a protein arises from contributions of aromatic residues in asymmetric environments, which is characteristic of native protein conformations [22], and it is very sensitive to small changes such as the binding of compounds near those aromatic residues. Therefore modifications of the near-UV CD spectrum of a protein in presence of a given compounds reveals binding. However, the reverse needs not be necessarily true, because binding can occur far away from contributing aromatic residues. To find further proof that 3-MP, compound 1 and compound 2 bind to PEPCK-C, the near-UV CD spectra of the enzymes in presence of those compounds were recorded. As can be seen in Fig 7, 3-MP and more markedly compound 2 modify the CD spectra of both isoenzymes. However, there were no clear differences in the enzyme CD spectra when 50 μM (Fig 7C and 7D) or 150 μM (data not shown) of compound 1 was added to a PEPCK-C solution. This may be indicative of, although it does not prove it, a weaker binding of compound 1 to PEPCK-C, compared to 3-MP and compound 2, as additionally suggested by its weaker inhibitory effect.

Download:

Fig 7. Near-UV CD spectra of PEPCK-C isoenzymes.

50 μM 3-MP (A-B), compound 1 (C-D) or compound 2 (E-F) were added to 20 μM PEPCK-C in a 20 mM HEPES pH 7.4 buffer and 1 mM TCEP.

https://doi.org/10.1371/journal.pone.0159002.g007

3.6. Isothermal titration calorimetry (ITC)

In order to prove that Met139Leu substitution and the inhibitor binding affects the nucleotide binding site, we performed ITC experiments in the presence or the absence of nucleotide. The results of these experiments are shown in Fig 8 and the derived thermodynamic parameters are summarized in Table 4. We have compared 139Met and 139Leu, 3-MP and compound 2, both in the presence and the absence of GTP. We have chosen GTP because the kinetic differences between isoenzymes were larger with GTP than with GDP.

Download:

Fig 8. ITC measurements of PEPCK-C isoenzymes with 3-MP or compound 2.

The upper part of each panel shows the thermogram after baseline correction, and the lower part shows the binding isotherm with the fit to a single class of binding sites model. (A) 139Met with 3-MP. (B) 139Met with compound 2.

https://doi.org/10.1371/journal.pone.0159002.g008

Download:

Table 4. ITC derived thermodynamic parameters.

https://doi.org/10.1371/journal.pone.0159002.t004

The dissociation constant (K_d) describes the affinity between a protein and a ligand. In all experiments, the Met139Leu substitution reduces the affinity of the inhibitors (Table 4). In the case of 3-MP, K_d values are 7.2 μM and 12 μM for 139Met and 139Leu, respectively, whereas in the case of compound 2 K_d values are 4.4 μM for 139Met and 9.8 for 139Leu. The presence of GTP further reduces the affinity of the 3-MP (19 μM for 139Met and 39 μM for 139Leu). Nevertheless, the presence of GTP raises the affinity of the compound 2 (19 μM for 139Met and 14 μM for 139Leu), although K_d values are different in presence and absence of GTP.

Enthalpy (ΔH) follows the same pattern of differences showed in K_d values. The negative enthalpy produced in all experiments showed that the binding of 3-MP and compound 2 are enthalpically driven.

There are clear-cut differences in the stoichiometry parameter (n) between 3-MP and compound 2 binding. The n values for 3-MP are around 2 and for compound 2 are close to 1. This indicates that there exist only one binding site for compound 2 in both isoenzymes but two binding sites for 3-MP, also in both isoenzymes.

Discussion

In a previous work [9] we found two isoenzymes in porcine PEPCK-C that differed considerably in their kinetic and functional properties. Those differences were translated into considerable differences in pig and pork phenotypic traits of considerable economic relevance. In this work we have continued the biochemical characterization of both isoenzymes and we have used them as a model system to search for new inhibitors able to modulate PEPCK-C activity due to the relevance of PEPCK-C activity in pathological processes.

To further investigate the catalytic differences between PEPCK-C isoenzymes 139Met and 139Leu we decided to use a known inhibitor, 3-MP, one of the first specific inhibitors of PEPCK-C described [15]. In our previous work [9], the largest kinetic differences between pig isoenzymes were detected in their interaction with nucleotides; here again both isoenzymes show the largest differences when the inhibition is studied varying a nucleotide, GTP. This means that the Met139Leu substitution affects probably the structure of the enzyme active site around the nucleotide binding site.

We have found the rather uncommon uncompetitive inhibition pattern of both PEPCK-C isoenzymes when both nucleotides (GDP and GTP) were used as variable substrate. This inhibition pattern requires a prior binding of the substrate to the active site in order to make the inhibitor site accessible. Recently, Balan et al. [23] found a very similar result studying the inhibition of rat PEPCK-C by 3-MP using both kinetic experiments and the determination of the 3D structure of the protein with bound 3-MP. They find uncompetitive inhibition when using GDP or GTP as variable substrates. However, their structural determinations showed that 3-MP had two binding sites: one in the active site that was responsible for the competitive component of their kinetic experiments, and the other one close to the active site and able to influence allosterically the binding of substrates and inhibitors to the active site. These structural data are not compatible with the apparent uncompetitive character of 3-MP inhibition because uncompetitive inhibition requires the existence of independent (or different) substrate and inhibitor binding sites [24]. Balan et al. [23] explain their results suggesting that the anomalous uncompetitive inhibition detected by kinetic means is due to the communication between the allosteric inhibitor site and the active site. Whatever is the true nature of the inhibition by 3-MP, this inhibitor serves to demonstrate the existence of further biochemical differences between pig PEPCK-C isoenzymes because the comparison of K_i values for 3-MP in the presence of GTP showed strong differences between pig isoenzymes. 139Met has an almost three fold larger affinity for 3-MP than 139Leu (273 vs 873 μM). We found no difference between PEPCK-C isoenzymes when analyzing 3-MP effects on PEP binding and only slight ones when analyzing its effects on OAA binding (K_i for139Leu is 50% larger than for 139Met). The inhibition mode for PEP and OAA was the same for both isoenzymes and substrates, a mixed non-competitive one.

The screening of the chemical library with 10,000 compounds yielded two positive compounds that stabilize the enzyme increasing the T_m around 8°C. The positive compounds were N1-cyclohexyl-2-{1-[4-methyl-2-(2-thienyl)-1,3-thiazol-5-yl]ethylidene}hydrazine-1-carbothiamide, or compound 1, and N'1-({5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl}methylidene)-2,4-dichlorobenzene-1-carbohydrazide, or compound 2.

In general, the effects of both compound 1 and 2 on V_max are stronger than on K_m values, which suggests that their inhibition mode is different from that of 3-MP and that they could have a different binding site than 3-MP. On the other hand, the structural similarity of compounds 1 and 2 (Fig 4) suggest these two compounds may share a common binding site.

There were quantitative differences between the inhibitory effects of compound 2 on 139Met and 139Leu: using OAA as a variable substrate, V_max values were 4.6 and 12.7 μmol min^-1 mg^-1 for 139Met and 139Leu, respectively. This significant difference showed that 139Met was more sensitive to compound 2 than 139Leu. Another significant difference when using GTP as a variable substrate was that K_m value of 139Met raised 2.5-fold in presence of compound 2, whereas 139Leu K_m decreased around 30%. As we report with 3-MP, compound 2 constitutes a valuable tool to investigate the biochemical differences between pig isoenzymes.

The results found in the ITC experiments show again differences between PEPCK-C isoenzymes when analyzing GTP binding. As it happened in the kinetic experiments (see Table 1), K_d for 3-MP of 139Met was much lower than that of 139Leu (19 vs 39 μM) in the presence of GTP, which resembles the effects found on K_i values in the kinetic experiments. ITC experiments showed also very different stoichiometry when studying 3-MP and compound 2 binding. Whereas n was 1 in all experiments using compound 2, we found a value of 2 when using 3-MP. As this parameter reflects the number of binding sites, our results suggest that there is only one binding site for compound 2 but two sites for 3-MP, in agreement with two 3-MP binding sites reported in the crystallographic structure of rat PEPCK-C by Balan et al. [23].

The study by ITC of compound 2 binding resembles also the kinetic results (see Table 3): the affinity of the 139Met isoenzyme (19 μM) for compound 2 in the presence of GTP is slightly lower than that of the 139Leu isoenzyme (14 μM).

The existence of notable differences between K_d values for both isoenzymes in the presence and in the absence of GTP (Table 4) confirms that both inhibitors affect the nucleotide binding site. The sites of 3-MP binding have been already determined by Balan et al. [23]; our results with compound 2 do not allow us to specify where the binding site for this inhibitor is located.

Most PEPCK-C effectors described in the literature are substrate analogues acting mainly as competitive inhibitors [15]. Finding new PEPCK-C inhibitors is important because of the PEPCK-C role in diabetes and cancer. PEPCK-C has been identified as a major contributing factor for the appearance of diabetes mellitus type 2 [25]. Cancer cells may overexpress PEPCK-C to avoid the decreased levels of glucose due to the preponderance of glycolysis in tumor areas [6]. New effectors with different patterns of inhibition could be interesting due to the potential existence of synergistic effects between inhibitors with different binding sites.

IC₅₀ values of compounds 1 and 2 are rather low which means that these inhibitors could be used as in vivo effectors. However, their poor solubility and their slight interaction with auxiliary enzymes indicate that compounds 1 and 2 are not very selective inhibitors and that they would need some improvement before they can be used as in vivo PEPCK-C effectors. Directed chemical modification of compounds 1 or 2 to improve their solubility and specificity could yield suitable effectors against diabetes or cancer.

In conclusion, the use of inhibitors reveals further biochemical differences between pig PEPCK-C isoenzymes reinforcing the idea that the Met139Leu substitution affects mainly the GTP/GDP binding site. The new PEPCK-C inhibitors found in this study could be helpful to modulate PEPCK-C activity in vivo if their solubility and selectivity could be improved.

Supporting Information

S1 Fig. Concentration-dependent inhibition of PEPCK-C by 3-MP.

Data are the mean of three independent experiments ± SD.

https://doi.org/10.1371/journal.pone.0159002.s001

(TIF)

S2 Fig. Dixon plots of 3-MP adding PEP and GDP as variable substrates.

(A) Dixon plot of 139Met varying PEP. (B) Dixon plot of 139Leu varying PEP. (C) Dixon plot of 139Met at saturating concentration of GDP. (D) Dixon plot of 139Leu at saturating concentration of GDP.

https://doi.org/10.1371/journal.pone.0159002.s002

(TIF)

S3 Fig. Dixon plots of 3-MP adding OAA and GTP as variable substrates.

(A) Dixon plot of 139Met varying OAA. (B) Dixon plot of 139Leu varying OAA. (C) Dixon plot of 139Met at saturating concentration of GTP. (D) Dixon plot of 139Leu at saturating concentration of GTP.

https://doi.org/10.1371/journal.pone.0159002.s003

(TIF)

S4 Fig. Concentration-dependent inhibition of PEPCK-C by compounds 1 and 2.

Data are the mean of three independent experiments ± SD. Compound 1 plot (A) was adjusted to linear regression due to its precipitation above 200 μM.

https://doi.org/10.1371/journal.pone.0159002.s004

(TIF)

Acknowledgments

This study was supported by research grants AGL2008-01487ALI (www.mineco.gob.es), DGA-IAF FITE2012/2013 (www.aragob.es), and UZ2014-CIE-03 (www.unizar.es) to P.L.B., AGL2015-66177 to P.L.B. and J.A.C., and grants BFU2013-47064-P (www.micinn.es), BIO2014-57314-REDT (www.mineco.gob.es) and PI078/08 to J.S. P.L. was supported by a predoctoral fellowship of Fundación La Caixa. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

Conceived and designed the experiments: PLB. Performed the experiments: JH PL. Analyzed the data: JH JAC AVC JS PLB. Contributed reagents/materials/analysis tools: PL. Wrote the paper: JH JAC AVC JS PLB.

References

1. Lagunas R, Gancedo C. Role of phosphate in the regulation of the Pasteur effect in Saccharomyces cerevisiae. Eur. J. Biochem. 1983;137(3):479–483. pmid:6229402
- View Article
- PubMed/NCBI
- Google Scholar
2. Case CL, Mukhopadhyay B. Kinetic characterization of recombinant human cytosolic phosphoenolpyruvate carboxykinase with and without a His₁₀-tag. Biochim. Biophys. Acta 2007;1770:1576–1584. pmid:17888579
- View Article
- PubMed/NCBI
- Google Scholar
3. Yang J, Kalhan SC, Hanson RW. What Is the Metabolic Role of Phosphoenolpyruvate Carboxykinase? J. Biol. Chem. 2009 October 02;284(40):27025–27029. pmid:19636077
- View Article
- PubMed/NCBI
- Google Scholar
4. Beale E, Harvey B, Forest C. PCK1 and PCK2 as candidate diabetes and obesity genes. Cell Biochem. Biophys. 2007 07/01;48(2–3):89–95. pmid:17709878
- View Article
- PubMed/NCBI
- Google Scholar
5. Bergman RN, Ader M. Free Fatty Acids and Pathogenesis of Type 2 Diabetes Mellitus. Trends Endocrinol. Metab. 2000 11/1;11(9):351–356. pmid:11042464
- View Article
- PubMed/NCBI
- Google Scholar
6. Leithner K, Hrzenjak A, Trotzmuller M, Moustafa T, Kofeler HC, Wohlkoenig C, et al. PCK2 activation mediates an adaptive response to glucose depletion in lung cancer. Oncogene 2015 02/19;34(8):1044–1050. pmid:24632615
- View Article
- PubMed/NCBI
- Google Scholar
7. Zhang P, Tu B, Wang H, Cao Z, Tang M, Zhang C, et al. Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion. Proc. Natl. Acad. Sci. U.S.A. 2014 July 22;111(29):10684–10689. pmid:25009184
- View Article
- PubMed/NCBI
- Google Scholar
8. Hakimi P, Yang J, Casadesus G, Massillon D, Tolentino-Silva F, Nye CK, et al. Overexpression of the Cytosolic Form of Phosphoenolpyruvate Carboxykinase (GTP) in Skeletal Muscle Repatterns Energy Metabolism in the Mouse. J. Biol. Chem. 2007 November 09;282(45):32844–32855. pmid:17716967
- View Article
- PubMed/NCBI
- Google Scholar
9. Latorre P, Burgos C, Hidalgo J, Varona L, Carrodeguas JA, López-Buesa P. c.A2456C-substitution in Pck1 changes the enzyme kinetic and functional properties modifying fat distribution in pigs. Sci. Rep. 2016 6, 19617 pmid:26792594
- View Article
- PubMed/NCBI
- Google Scholar
10. Yang J, Reshef L, Cassuto H, Aleman G, Hanson RW. Aspects of the Control of Phosphoenolpyruvate Carboxykinase Gene Transcription J. Biol. Chem. 2009 July 27;284:27031–27035.
- View Article
- Google Scholar
11. Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu. Rev. Biochem. 1997 06/01; 2015/06;66(1):581–611.
- View Article
- Google Scholar
12. Jiang W, Wang S, Xiao M, Lin Y, Zhou L, Lei Q, et al. Acetylation Regulates Gluconeogenesis by Promoting PEPCK1 Degradation via Recruiting the UBR5 Ubiquitin Ligase. Mol. Cell 2011 7/8;43(1):33–44. pmid:21726808
- View Article
- PubMed/NCBI
- Google Scholar
13. Warburg O. On the Origin of Cancer Cells. Science 1956 02/24;123(3191):309–314. pmid:13298683
- View Article
- PubMed/NCBI
- Google Scholar
14. Lyne PD. Structure-based virtual screening: an overview. Drug Discov. Today 2002 10/15;7(20):1047–1055.
- View Article
- Google Scholar
15. Stiffin RM, Sullivan SM, Carlson GM, Holyoak T. Differential Inhibition of Cytosolic PEPCK by Substrate Analogues. Kinetic and Structural Characterization of Inhibitor Recognition. Biochemistry 2008 02/01;47(7):2099–2109 pmid:18197707
- View Article
- PubMed/NCBI
- Google Scholar
16. Robinson BH, Oei J. 3-Mercaptopicolinic acid, a preferential inhibitor of the cytosolic phosphoenolpyruvate carboxykinase. FEBS Lett. 1975 10/15;58(1–2):12–15.
- View Article
- Google Scholar
17. Foley LH, Wang P, Dunten P, Ramsey G, Gubler M, Wertheimer SJ. Modified 3-Alkyl-1,8-dibenzylxanthines as GTP-Competitive inhibitors of phosphoenolpyruvate carboxykinase. Bioorg. Med. Chem. Lett. 2003 10/20;13(20):3607–3610. pmid:14505680
- View Article
- PubMed/NCBI
- Google Scholar
18. Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ, Wasney GA, et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. U.S.A. 2006 October 24;103(43):15835–15840. pmid:17035505
- View Article
- PubMed/NCBI
- Google Scholar
19. Shoichet BK. Virtual screening of chemical libraries. Nature 2004 12/16;432(7019):862–865. pmid:15602552
- View Article
- PubMed/NCBI
- Google Scholar
20. Cremades N, Velázquez-Campoy A, Martínez-Júlvez M, Neira JL, Pérez-Dorado I, Hermoso J, et al. Discovery of Specific Flavodoxin Inhibitors as Potential Therapeutic Agents against Helicobacter pylori Infection. ACS Chem. Biol. 2009 11/20;4(11):928–938. pmid:19725577
- View Article
- PubMed/NCBI
- Google Scholar
21. Pey AL, Ying M, Cremades N, Velázquez-Campoy A, Scherer T, Thöny B, et al. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J. Clin. Invest. 2008 08/01;118(8):2858–2867. pmid:18596920
- View Article
- PubMed/NCBI
- Google Scholar
22. Vuilleumier S, Sancho J, Loewenthal R, Fersht AR. Circular dichroism studies of barnase and its mutants: Characterization of the contribution of aromatic side chains. Biochemistry 1993 10/01;32(39):10303–10313. pmid:8399173
- View Article
- PubMed/NCBI
- Google Scholar
23. Balan MD, Mcleod MJ, Lotosky WR, Ghaly M, Holyoak T. Inhibition and Allosteric Regulation of Monomeric Phosphoenolpyruvate Carboxykinase by 3-Mercaptopicolinic Acid. Biochemistry 2015 09/29;54(38):5878–5887 pmid:26322521
- View Article
- PubMed/NCBI
- Google Scholar
24. Copeland RA. Enzymes: a practical introduction to structure, mechanism and data analysis. 2nd ed.: Wiley-VCH; 2000.
25. Valera A, Pujol A, Pelegrin M, Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. U.S.A. 1994 September 13;91(19):9151–9154. pmid:8090784
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. Lagunas R, Gancedo C. Role of phosphate in the regulation of the Pasteur effect in Saccharomyces cerevisiae. Eur. J. Biochem. 1983;137(3):479–483. pmid:6229402
View Article
PubMed/NCBI
Google Scholar

[2] View Article

[3] PubMed/NCBI

[4] Google Scholar

[ref2] 2. Case CL, Mukhopadhyay B. Kinetic characterization of recombinant human cytosolic phosphoenolpyruvate carboxykinase with and without a His₁₀-tag. Biochim. Biophys. Acta 2007;1770:1576–1584. pmid:17888579
View Article
PubMed/NCBI
Google Scholar

[6] View Article

[7] PubMed/NCBI

[8] Google Scholar

[ref3] 3. Yang J, Kalhan SC, Hanson RW. What Is the Metabolic Role of Phosphoenolpyruvate Carboxykinase? J. Biol. Chem. 2009 October 02;284(40):27025–27029. pmid:19636077
View Article
PubMed/NCBI
Google Scholar

[10] View Article

[11] PubMed/NCBI

[12] Google Scholar

[ref4] 4. Beale E, Harvey B, Forest C. PCK1 and PCK2 as candidate diabetes and obesity genes. Cell Biochem. Biophys. 2007 07/01;48(2–3):89–95. pmid:17709878
View Article
PubMed/NCBI
Google Scholar

[14] View Article

[15] PubMed/NCBI

[16] Google Scholar

[ref5] 5. Bergman RN, Ader M. Free Fatty Acids and Pathogenesis of Type 2 Diabetes Mellitus. Trends Endocrinol. Metab. 2000 11/1;11(9):351–356. pmid:11042464
View Article
PubMed/NCBI
Google Scholar

[18] View Article

[19] PubMed/NCBI

[20] Google Scholar

[ref6] 6. Leithner K, Hrzenjak A, Trotzmuller M, Moustafa T, Kofeler HC, Wohlkoenig C, et al. PCK2 activation mediates an adaptive response to glucose depletion in lung cancer. Oncogene 2015 02/19;34(8):1044–1050. pmid:24632615
View Article
PubMed/NCBI
Google Scholar

[22] View Article

[23] PubMed/NCBI

[24] Google Scholar

[ref7] 7. Zhang P, Tu B, Wang H, Cao Z, Tang M, Zhang C, et al. Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion. Proc. Natl. Acad. Sci. U.S.A. 2014 July 22;111(29):10684–10689. pmid:25009184
View Article
PubMed/NCBI
Google Scholar

[26] View Article

[27] PubMed/NCBI

[28] Google Scholar

[ref8] 8. Hakimi P, Yang J, Casadesus G, Massillon D, Tolentino-Silva F, Nye CK, et al. Overexpression of the Cytosolic Form of Phosphoenolpyruvate Carboxykinase (GTP) in Skeletal Muscle Repatterns Energy Metabolism in the Mouse. J. Biol. Chem. 2007 November 09;282(45):32844–32855. pmid:17716967
View Article
PubMed/NCBI
Google Scholar

[30] View Article

[31] PubMed/NCBI

[32] Google Scholar

[ref9] 9. Latorre P, Burgos C, Hidalgo J, Varona L, Carrodeguas JA, López-Buesa P. c.A2456C-substitution in Pck1 changes the enzyme kinetic and functional properties modifying fat distribution in pigs. Sci. Rep. 2016 6, 19617 pmid:26792594
View Article
PubMed/NCBI
Google Scholar

[34] View Article

[35] PubMed/NCBI

[36] Google Scholar

[ref10] 10. Yang J, Reshef L, Cassuto H, Aleman G, Hanson RW. Aspects of the Control of Phosphoenolpyruvate Carboxykinase Gene Transcription J. Biol. Chem. 2009 July 27;284:27031–27035.
View Article
Google Scholar

[38] View Article

[39] Google Scholar

[ref11] 11. Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu. Rev. Biochem. 1997 06/01; 2015/06;66(1):581–611.
View Article
Google Scholar

[41] View Article

[42] Google Scholar

[ref12] 12. Jiang W, Wang S, Xiao M, Lin Y, Zhou L, Lei Q, et al. Acetylation Regulates Gluconeogenesis by Promoting PEPCK1 Degradation via Recruiting the UBR5 Ubiquitin Ligase. Mol. Cell 2011 7/8;43(1):33–44. pmid:21726808
View Article
PubMed/NCBI
Google Scholar

[44] View Article

[45] PubMed/NCBI

[46] Google Scholar

[ref13] 13. Warburg O. On the Origin of Cancer Cells. Science 1956 02/24;123(3191):309–314. pmid:13298683
View Article
PubMed/NCBI
Google Scholar

[48] View Article

[49] PubMed/NCBI

[50] Google Scholar

[ref14] 14. Lyne PD. Structure-based virtual screening: an overview. Drug Discov. Today 2002 10/15;7(20):1047–1055.
View Article
Google Scholar

[52] View Article

[53] Google Scholar

[ref15] 15. Stiffin RM, Sullivan SM, Carlson GM, Holyoak T. Differential Inhibition of Cytosolic PEPCK by Substrate Analogues. Kinetic and Structural Characterization of Inhibitor Recognition. Biochemistry 2008 02/01;47(7):2099–2109 pmid:18197707
View Article
PubMed/NCBI
Google Scholar

[55] View Article

[56] PubMed/NCBI

[57] Google Scholar

[ref16] 16. Robinson BH, Oei J. 3-Mercaptopicolinic acid, a preferential inhibitor of the cytosolic phosphoenolpyruvate carboxykinase. FEBS Lett. 1975 10/15;58(1–2):12–15.
View Article
Google Scholar

[59] View Article

[60] Google Scholar

[ref17] 17. Foley LH, Wang P, Dunten P, Ramsey G, Gubler M, Wertheimer SJ. Modified 3-Alkyl-1,8-dibenzylxanthines as GTP-Competitive inhibitors of phosphoenolpyruvate carboxykinase. Bioorg. Med. Chem. Lett. 2003 10/20;13(20):3607–3610. pmid:14505680
View Article
PubMed/NCBI
Google Scholar

[62] View Article

[63] PubMed/NCBI

[64] Google Scholar

[ref18] 18. Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ, Wasney GA, et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. U.S.A. 2006 October 24;103(43):15835–15840. pmid:17035505
View Article
PubMed/NCBI
Google Scholar

[66] View Article

[67] PubMed/NCBI

[68] Google Scholar

[ref19] 19. Shoichet BK. Virtual screening of chemical libraries. Nature 2004 12/16;432(7019):862–865. pmid:15602552
View Article
PubMed/NCBI
Google Scholar

[70] View Article

[71] PubMed/NCBI

[72] Google Scholar

[ref20] 20. Cremades N, Velázquez-Campoy A, Martínez-Júlvez M, Neira JL, Pérez-Dorado I, Hermoso J, et al. Discovery of Specific Flavodoxin Inhibitors as Potential Therapeutic Agents against Helicobacter pylori Infection. ACS Chem. Biol. 2009 11/20;4(11):928–938. pmid:19725577
View Article
PubMed/NCBI
Google Scholar

[74] View Article

[75] PubMed/NCBI

[76] Google Scholar

[ref21] 21. Pey AL, Ying M, Cremades N, Velázquez-Campoy A, Scherer T, Thöny B, et al. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J. Clin. Invest. 2008 08/01;118(8):2858–2867. pmid:18596920
View Article
PubMed/NCBI
Google Scholar

[78] View Article

[79] PubMed/NCBI

[80] Google Scholar

[ref22] 22. Vuilleumier S, Sancho J, Loewenthal R, Fersht AR. Circular dichroism studies of barnase and its mutants: Characterization of the contribution of aromatic side chains. Biochemistry 1993 10/01;32(39):10303–10313. pmid:8399173
View Article
PubMed/NCBI
Google Scholar

[82] View Article

[83] PubMed/NCBI

[84] Google Scholar

[ref23] 23. Balan MD, Mcleod MJ, Lotosky WR, Ghaly M, Holyoak T. Inhibition and Allosteric Regulation of Monomeric Phosphoenolpyruvate Carboxykinase by 3-Mercaptopicolinic Acid. Biochemistry 2015 09/29;54(38):5878–5887 pmid:26322521
View Article
PubMed/NCBI
Google Scholar

[86] View Article

[87] PubMed/NCBI

[88] Google Scholar

[ref24] 24. Copeland RA. Enzymes: a practical introduction to structure, mechanism and data analysis. 2nd ed.: Wiley-VCH; 2000.

[ref25] 25. Valera A, Pujol A, Pelegrin M, Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. U.S.A. 1994 September 13;91(19):9151–9154. pmid:8090784
View Article
PubMed/NCBI
Google Scholar

[91] View Article

[92] PubMed/NCBI

[93] Google Scholar

Figures

Abstract

Introduction

Materials and Methods

2.1. Enzymes and chemicals

2.2. PEPCK-C purification

2.3. Screening of chemical library

2.4. Enzymatic assays

2.5. Determination of kinetic parameters

2.6. Circular dichroism (CD)

2.7. Isothermal titration calorimetry (ITC)

2.8. Statistical analysis

Results

3.1. Inhibition with 3-MP

3.2. Screening of chemical library

3.3. Inhibition with compound 1

3.4. Inhibition with compound 2

3.5. CD spectra

3.6. Isothermal titration calorimetry (ITC)

Discussion

Supporting Information

S1 Fig. Concentration-dependent inhibition of PEPCK-C by 3-MP.

S2 Fig. Dixon plots of 3-MP adding PEP and GDP as variable substrates.

S3 Fig. Dixon plots of 3-MP adding OAA and GTP as variable substrates.

S4 Fig. Concentration-dependent inhibition of PEPCK-C by compounds 1 and 2.

Acknowledgments

Author Contributions

References